Open an account

GlucoTrack

GCTK · NASDAQ

$0.6511−$0.0336 (−4.91%)TodayMarket closed ·
Prev close $0.6847

About GCTK

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 15 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.

Employees
11
Headquarters
Rutherford, New Jersey
Listed
Apr 9, 2013
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
glucotrack.com

GCTK key statistics

Market cap
1.54M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.24M
Volume
50.93K
Open price
$0.677
High today
$0.6775
Low today
$0.59
52 Week high
$112.50
52 Week low
$0.682

GlucoTrack (GCTK) at a glance

GlucoTrack (GCTK) last traded at $0.6511, with a market cap of 1.54M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.59 and $0.6775. The current price is 10.4% above the day's low and 3.9% below its high.

Volume so far is 50.93K shares, below the average of 4.24M shares a day.

Over the past year GlucoTrack has ranged from $0.682 to $112.50, and now sits 0% of the way up that range.

GCTK news

  • Press releaseBusiness Wire

    Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications

  • Press releaseBusiness Wire

    Lōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität Paderborn

  • Press releaseBusiness Wire

    Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14

  • Press releaseBusiness Wire

    Lōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™

  • Press releaseBusiness Wire

    Glucotrack, Inc. Announces Pricing of $3 Million Public Offering

  • Press releaseBusiness Wire

    Lōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating Platform

  • Press releaseBusiness Wire

    Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities

  • Press releaseBusiness Wire

    Lōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma Talent

Similar companies

Companies in the same industry as GlucoTrack

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.